ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.693,37
0,04%
S&P 500
5.304,72
0,70%
Dow Jones
39.069,59
0,01%
Euro vs US Dollar
1,08485
0,00%
Bitcoin
69.129,55
-0,20%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Inhibikase Therapeutics Inc (IKT)

  7. Inhibikase Therapeutics Inc (IKT) News

IKT

Inhibikase Therapeutics (IKT)

Inhibikase Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:IKT
DatumZeitQuelleÜberschriftSymbolFirma
22/05/202414h55Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IKTInhibikase Therapeutics Inc
20/05/202414h55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IKTInhibikase Therapeutics Inc
20/05/202414h01GlobeNewswire Inc.Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 MillionNASDAQ:IKTInhibikase Therapeutics Inc
20/05/202413h09Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IKTInhibikase Therapeutics Inc
16/05/202402h00GlobeNewswire Inc.Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period ActivityNASDAQ:IKTInhibikase Therapeutics Inc
15/05/202423h04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IKTInhibikase Therapeutics Inc
15/05/202414h45GlobeNewswire Inc.Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration StatementNASDAQ:IKTInhibikase Therapeutics Inc
15/05/202413h56Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:IKTInhibikase Therapeutics Inc
09/05/202420h41Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:IKTInhibikase Therapeutics Inc
09/05/202414h00GlobeNewswire Inc.Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial HypertensionNASDAQ:IKTInhibikase Therapeutics Inc
18/04/202422h30GlobeNewswire Inc.Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development ProgramsNASDAQ:IKTInhibikase Therapeutics Inc
03/04/202414h05GlobeNewswire Inc.Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial HypertensionNASDAQ:IKTInhibikase Therapeutics Inc
27/03/202421h15GlobeNewswire Inc.Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent ActivityNASDAQ:IKTInhibikase Therapeutics Inc
07/03/202414h30GlobeNewswire Inc.Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological DisordersNASDAQ:IKTInhibikase Therapeutics Inc
28/02/202422h05GlobeNewswire Inc.Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001ProNASDAQ:IKTInhibikase Therapeutics Inc
07/02/202413h59Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IKTInhibikase Therapeutics Inc
07/02/202413h55GlobeNewswire Inc.Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal CancersNASDAQ:IKTInhibikase Therapeutics Inc
01/02/202422h49Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IKTInhibikase Therapeutics Inc
01/02/202422h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IKTInhibikase Therapeutics Inc
29/01/202415h05GlobeNewswire Inc.Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with RisvodetinibNASDAQ:IKTInhibikase Therapeutics Inc
16/01/202422h31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IKTInhibikase Therapeutics Inc
16/01/202422h05GlobeNewswire Inc.Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph FrattaroliNASDAQ:IKTInhibikase Therapeutics Inc
19/12/202314h30GlobeNewswire Inc.Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development ProgramsNASDAQ:IKTInhibikase Therapeutics Inc
04/12/202314h35GlobeNewswire Inc.Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001ProNASDAQ:IKTInhibikase Therapeutics Inc
14/11/202322h30GlobeNewswire Inc.Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period ActivityNASDAQ:IKTInhibikase Therapeutics Inc
07/11/202315h28GlobeNewswire Inc.Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023NASDAQ:IKTInhibikase Therapeutics Inc
07/11/202314h00GlobeNewswire Inc.Inhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023NASDAQ:IKTInhibikase Therapeutics Inc
16/10/202323h24Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:IKTInhibikase Therapeutics Inc
16/10/202313h00GlobeNewswire Inc.Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing EnrollmentNASDAQ:IKTInhibikase Therapeutics Inc
04/10/202314h30GlobeNewswire Inc.Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System AtrophyNASDAQ:IKTInhibikase Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:IKT

Kürzlich von Ihnen besucht

BIT
S24981
SG ISSUER
USOTC
AFCL
Amcor Financial (CE)
USOTC
DEXCF
Dexerials (PK)
ASX
CVNNA
BIT
P1WOR0
NLBNPIT1WOR0 20240619 15...
ASX
MMS
Mcmillan Shakespeare
BOV
PETRG247
PETRG247 Ex:21,87
NASDAQ
FVUGOX
S&P Dividend Aristocrats...
LSE
0EG7
Fernheizwerk Neukoelln
BOV
A1ES34R
AES
LSE
IUGA
Us Agg Etf Gb-h
COIN
DVTGBP
DeVault
TSXV
GLK.H
Great Lakes Graphite
BIT
F14403
Vontobel Financial Produ...
LSE
JZCN
BIT
P1WE34
NLBNPIT1WE34 20240621 3.2
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten